ClinicalTrials.gg
RecruitingNCT06316167Updated Mar 18, 2024

Mandatory Hiatoplasty in Sleeve Gastrectomy for Gastro-Esophageal Reflux Disease

An observational study in Postgastrectomy Syndromes and Gastroesophageal Reflux, sponsored by Instituto Mexicano del Seguro Social. Recruiting at 1 site in Mexico. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-18.

Sponsored by Instituto Mexicano del Seguro Social · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 3 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
275
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Gastroesophageal Reflux with a site in Mexico — 3 open to participants now, 3 under way, none of them phase 3. Gastroesophageal Reflux · Mexico.

Started
2024
with 1 other
Observational
2 of 14
1 open now
Registered
13th of 14
by date
Lead sponsor
1 of 14
Instituto Mexicano del Seguro Social

Among the 14 studies in Gastroesophageal Reflux with a site in Mexico, this one is one of 2 that started in 2024, is one of 2 observational ones, and was the 13th registered.

Gastroesophageal Reflux

1,216 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

3 of the 14 studies in Gastroesophageal Reflux with a site in Mexico are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →

Who these studies take

Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Gastroesophageal Reflux with a site in Mexico, or all of them as a file.
02

Study summary

The goal of this observational study is to learn about incidence of postoperative gastroesophageal reflux disease in mandatory hiatoplasty performed during gastric sleeve surgery.

The main question[s] it aims to answer are:

  • Incidence of postoperative GERD in patients undergoing gastric sleeve with mandatory hiatoplasty
  • Comparison of postoperative complication rates, including GERD

Participants will answer a follow-up questionnaire, about postoperative quality of life

03

Conditions studied

  • Postgastrectomy Syndromes
  • Gastroesophageal Reflux

Keywords

  • Incidence
  • Complications
  • Bariatric surgery
  • Obesity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients over 18 years of age of indistinct gender who underwent gastric sleeve with hiatoplasty for obesity or overweight management in a hospital center specialized in bariatric surgery in Tijuana, Baja California.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients over 18 years of age.
  • Gender indistinct.
  • Overweight, obesity grade I, II, III, super obesity or super-super obesity.
  • Underwent gastric sleeve with hiatoplasty for obesity management at a high volume Tijuana hospital dedicated to bariatric surgery.

Exclusion criteria

Exclusion Criteria:

  • Patient records with incomplete information.
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
275 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Number of participants without postoperative GERD

    To evaluate the efficacy of mandatory hiatoplasty performed during gastric sleeve surgery in reducing the incidence of postoperative gastroesophageal reflux disease (GERD) in patients undergoing this procedure in a hospital specializing in bariatric surgery in Tijuana, Baja California.

    Time frame: 6 months

Secondary outcomes

  1. Comorbidities in patients undergoing gastric sleeve with hiatoplasty

    These patients usually have significant obesity, often accompanied by comorbidities such as type 2 diabetes, hypertension, sleep apnea, and gastroesophageal reflux disease (GERD).

    Time frame: 6 months

  2. Incidence of postoperative GERD in patients undergoing gastric sleeve with mandatory hiatoplasty

    Hiatoplasty is often performed to reduce the risk of postoperative GERD by repairing a herniated hiatus during gastric sleeve surgery. However, the exact incidence of postoperative GERD can vary and depends on factors such as surgical technique, patient anatomy and postoperative management.

    Time frame: 6 months

  3. Comparison of postoperative complication rates, including GERD

    Postoperative complications may include, but are not limited to, bleeding, infection, sleeve stenosis, and GERD recurrence. Comparison of complication rates between patients with and without mandatory hiatoplasty may provide insight into the effectiveness of this technique in mitigating specific risks.

    Time frame: 6 months

  4. Postoperative quality of life analysis

    Questionnaire postoperative quality of life with the Bariatric Analysis and Reporting Outcome System (BAROS) Questionnaire

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • Unidad de Investigación Biomédica 02, Unidad Médica de alta especialidad, Hospital de Especialidades Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara 44329, Mexico
    Guadalajara, Jalisco 44329, Mexico
    Recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Data will be kept absolutely confidential

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2024 (actual). Primary completion is estimated for Jul 2024, 4 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2024
First posted
Mar 18, 2024
StartActual
Mar 1, 2024
Primary completionEst.
Jul 31, 2024
CompletionEst.
Aug 31, 2024
Last update
Mar 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06316167
Responsible party
GONZALEZ-OJEDA ALEJANDRO (Principal Investigator, Instituto Mexicano del Seguro Social) — Principal investigator
First posted
Mar 18, 2024
Start date
Mar 1, 2024
Primary completion
Jul 31, 2024 (estimated)
Completion
Aug 31, 2024 (estimated)
Last update
Mar 18, 2024

Study contacts

Alejandro Gonzalez-Ojeda, MD, PhD
Contact
avygail5@gmail.com
3331294165
José Aldo Guzmán-Barba, MD, PhD
study chair · ALO Bariatrics. Gobernador Ibarra 9721, Zona Cacho, 22044, Tijuana, Baja California, México.
Alejandro López-Ortega, MD, PhD
study director · ALO Bariatrics. Gobernador Ibarra 9721, Zona Cacho, 22044, Tijuana, Baja California, México.
Helmut Heribert, MD, PhD
principal investigator · ALO Bariatrics. Gobernador Ibarra 9721, Zona Cacho, 22044, Tijuana, Baja California, México.
Isaac Esparza Estrada, MD, PhD
study chair · ALO Bariatrics. Gobernador Ibarra 9721, Zona Cacho, 22044, Tijuana, Baja California, México.
Sergio Jiram Vazquez-Sánchez, MD
study chair · Unidad de Investigación Biomédica 02, Unidad Médica de alta especialidad, Hospital de Especialidades Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara 44329, Mexico
Alejandro González-Ojeda, MD, PhD
study chair · Unidad de Investigación Biomédica 02, Unidad Médica de alta especialidad, Hospital de Especialidades Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara 44329, Mexico

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion